SCHEMBL4464349

SCHEMBL4464349

CS(=O)(=O)Nc1ccc(CC2=NNC(=O)C2=C2C=Cc3ccccc3N2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
KEAP1 Q14145 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
CYP2C9 P11712 1/20 0.34
NPC1 O15118 1/20 0.34
AR P10275 1/20 0.34
RAB9A P51151 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
NR3C2 P08235 2/20 0.33
TAS2R14 Q9NYV8 1/20 0.33
PIP4K2A P48426 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464344 1.00 HPGD (0.43) HPGDSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4460453 0.83 SMN1; SMN2 (0.41) HPGDSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4460455 0.83 SMN1; SMN2 (0.41) HPGDSMN1; SMN2KDM4EALDH1A1LMNA
SCHEMBL4460439 0.83 GAA (0.40) AR
SCHEMBL4460435 0.83 GAA (0.40) AR
SCHEMBL4470583 0.82 MAPT (0.37) SMN1; SMN2ALDH1A1LMNACA12CA1
SCHEMBL4470585 0.82 MAPT (0.37) SMN1; SMN2ALDH1A1LMNACA12CA1
SCHEMBL4462771 0.73 PKM (0.34) SMN1; SMN2ALDH1A1
SCHEMBL5999321 0.73 PKM (0.34) SMN1; SMN2ALDH1A1
SCHEMBL4460259 0.71 MAPT (0.46) SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 US claimed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 EP claimed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 WO claimed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 US claimed
US-7550598-B2 Kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-23 US disclosed
EP-1778669-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-05-02 EP disclosed
WO-2006023931-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-03-02 WO disclosed
US-20060041137-A1 Kinase inhibitors TAKEDA SAN DIEGO, INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060041137-A1 Kinase inhibitors MAP3K19, MAP3K20, MAP3K1 HPGD 3266/4885SMN1; SMN2 4388/4885KDM4E 864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.